| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4021f8d8a53258a5a3615b4139dd1eee |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate |
2014-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_489305a7a96fd115432d799ecca887d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c892423687a0243dce955f1ffe60f2f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68ef16cf775211b2476ef354cffb9f95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00f5c6df94cdc1b05cf3348ecda5cb50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f23203e8fa0fae8a0a4f1cd9bfacc2fb |
| publicationDate |
2019-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10239948-B2 |
| titleOfInvention |
Method of engineering multi-input signal sensitive T cell for immunotherapy |
| abstract |
The present invention relates to a method to engineer immune cell for immunotherapy. In particular said immune cells are engineered with chimeric antigen receptors, which be activated by the combination of hypoxia and ligand extracellular binding as input signals. The invention also relates to new designed chimeric antigen receptors which are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties and the hypoxia condition. The present invention also relates to cells obtained by the present method, in particular T-cells, comprising said chimeric antigen receptors for use in cancer treatments. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11717538-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10975368-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11708572-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10988541-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10785574-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11377651-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10704021-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10548921-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11214789-B2 |
| priorityDate |
2013-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |